JP2010504286A - スフィンゴシン−1−リン酸(s1p)受容体アゴニスト及び/又はアンタゴニスト生物活性を有するヘテロ芳香族化合物 - Google Patents

スフィンゴシン−1−リン酸(s1p)受容体アゴニスト及び/又はアンタゴニスト生物活性を有するヘテロ芳香族化合物 Download PDF

Info

Publication number
JP2010504286A
JP2010504286A JP2009527532A JP2009527532A JP2010504286A JP 2010504286 A JP2010504286 A JP 2010504286A JP 2009527532 A JP2009527532 A JP 2009527532A JP 2009527532 A JP2009527532 A JP 2009527532A JP 2010504286 A JP2010504286 A JP 2010504286A
Authority
JP
Japan
Prior art keywords
compound
group
mmol
compound according
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009527532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010504286A5 (enExample
Inventor
リチャード エル ベアード
ジョン イー ドネロ
ハイキン ユアン
シャオシャ リウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2010504286A publication Critical patent/JP2010504286A/ja
Publication of JP2010504286A5 publication Critical patent/JP2010504286A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
JP2009527532A 2006-09-07 2007-09-05 スフィンゴシン−1−リン酸(s1p)受容体アゴニスト及び/又はアンタゴニスト生物活性を有するヘテロ芳香族化合物 Pending JP2010504286A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82480706P 2006-09-07 2006-09-07
PCT/US2007/077588 WO2008030843A1 (en) 2006-09-07 2007-09-05 Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity

Publications (2)

Publication Number Publication Date
JP2010504286A true JP2010504286A (ja) 2010-02-12
JP2010504286A5 JP2010504286A5 (enExample) 2010-10-21

Family

ID=38961939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527532A Pending JP2010504286A (ja) 2006-09-07 2007-09-05 スフィンゴシン−1−リン酸(s1p)受容体アゴニスト及び/又はアンタゴニスト生物活性を有するヘテロ芳香族化合物

Country Status (6)

Country Link
EP (1) EP2066633A1 (enExample)
JP (1) JP2010504286A (enExample)
AU (1) AU2007292347A1 (enExample)
BR (1) BRPI0716815A2 (enExample)
CA (1) CA2662852A1 (enExample)
WO (1) WO2008030843A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005014271A1 (de) * 2005-03-24 2006-09-28 Rhein Chemie Rheinau Gmbh Mikrogele in Kombination mit funktionalen Additiven
WO2008141013A1 (en) * 2007-05-08 2008-11-20 Allergan, Inc. S1p3 receptor inhibitors for treating pain
KR20180023049A (ko) 2008-07-23 2018-03-06 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[b]인돌-3-일)아세트산 유도체
CN105816453B (zh) 2008-08-27 2021-03-05 艾尼纳制药公司 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
US8741875B2 (en) 2009-11-24 2014-06-03 Allergan, Inc. Compounds as receptor modulators with therapeutic utility
CA2780987C (en) * 2009-11-24 2018-03-06 Allergan, Inc. Novel compounds as receptor modulators with therapeutic utility
US8853419B2 (en) 2010-01-27 2014-10-07 Arena Pharmaceuticals, Inc. Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN102884064B (zh) 2010-03-03 2016-01-13 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
WO2011133734A1 (en) 2010-04-23 2011-10-27 Bristol-Myers Squibb Company 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
WO2011143332A1 (en) 2010-05-14 2011-11-17 Allergan, Inc. Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity
US8513220B2 (en) 2010-05-14 2013-08-20 Allergan, Inc. Aromatic compounds having sphingosine-1-phosphonate (S1P) receptor activity
EP2619190B1 (en) 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
EP3092231B1 (en) 2013-12-11 2018-06-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
DK3242666T5 (da) 2015-01-06 2025-01-20 Arena Pharm Inc Forbindelsee til anvendelse i behandling af tilstande, der er forbundet med SIP1-receptoren
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
MA47503A (fr) 2017-02-16 2021-04-21 Arena Pharm Inc Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
KR102836433B1 (ko) 2018-09-06 2025-07-21 아레나 파마슈티칼스, 인크. 자가면역 및 염증성 장애의 치료에 유용한 화합물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05508845A (ja) * 1990-07-24 1993-12-09 ローン―プーラン・ロレ・ソシエテ・アノニム 選択的ロイコトリエンb4拮抗活性を示す置換2環式ビス―アリール組成物、それらの調製および医薬組成物における使用
JPH06501926A (ja) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
WO2005058848A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05508845A (ja) * 1990-07-24 1993-12-09 ローン―プーラン・ロレ・ソシエテ・アノニム 選択的ロイコトリエンb4拮抗活性を示す置換2環式ビス―アリール組成物、それらの調製および医薬組成物における使用
JPH06501926A (ja) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
WO2005058848A1 (en) * 2003-12-17 2005-06-30 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN7013000025; Tetrahedron 56, 2000, pp.6319-6330 *
JPN7013000027; J.Org.Chem. 71(16), 2006, pp.5897-5905 *
JPN7013000028; Tetrahedron Letters 31, 1978, pp.2791-2794 *
JPN7013000030; Chem.Pharm.Bull. 13(10), 1965, pp.1168-1177 *
JPN7013000032; Helvetica Chimica Acta 38, 1955, pp.1560-1564 *
JPN7013000034; Chem.Pharm.Bull. 29(10), 1981, pp.2837-2843 *
JPN7013000035; J.Am.Chem.Soc. 78, 1956, pp.2141-2144 *
JPN7013000037; CHEM.COMMUN. , 2002, pp.1760-1761 *

Also Published As

Publication number Publication date
BRPI0716815A2 (pt) 2013-11-05
WO2008030843A1 (en) 2008-03-13
CA2662852A1 (en) 2008-03-13
EP2066633A1 (en) 2009-06-10
AU2007292347A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
JP2010504286A (ja) スフィンゴシン−1−リン酸(s1p)受容体アゴニスト及び/又はアンタゴニスト生物活性を有するヘテロ芳香族化合物
KR102872871B1 (ko) 모발 성장을 조절하기 위한 조성물 및 방법
CN101061105B (zh) 谷氨酸受体增效剂
CN101460458A (zh) 具有1-磷酸-鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚-3-羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
US7728014B2 (en) Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist biological activity
KR20080102181A (ko) 스핑고신-1-포스페이트 (에스1피) 수용체 길항제 생물학적 활성을 갖는 아릴 또는 헤테로아릴기를 포함하는 인돌-3-카르보실산 아미드, 에스테르, 티오아미드 및 티올 에스테르 화합물
JP2007524682A (ja) 代謝調節型グルタミン酸受容体−5の調節物質としてのビピリジルアミド
BG103689A (bg) Атропизомери на(3)арил-4(3н)-хиназолинони и използването им като амра-рецепторни антагонисти
KR20120129869A (ko) Mglur4 알로스테릭 강화제, 조성물 및 신경 기능이상을 치료하는 방법
RU2641003C2 (ru) Биарильные производные в качестве агонистов gpr120
CN102099333A (zh) 具有1-磷酸鞘氨醇(s1p)受体拮抗剂生物学活性的6-取代吲哚-3-羧酸酰胺化合物
JP2007504229A (ja) 代謝調節型グルタミン酸受容体−5のモジュレーターとしてのビピリジルアミン類およびエーテル類
CS36192A3 (en) Nitrogen hetero cycles, process of their preparation and pharmaceuticalcompositions containing said hetero cycles
CA2729552A1 (en) Aza-indoles and related compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
JP2010536871A (ja) スフィンゴシン−1−リン酸受容体アゴニストまたはアンタゴニスト生物学的活性を有するピロール化合物
US8507682B2 (en) Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (S1P2) receptors
FI95372C (fi) Menetelmä valmistaa terapeuttisesti arvokkaita aryylisulfonamideja
JP2010502728A (ja) スフィンゴシン−1−リン酸(s1p)受容体アゴニスト生物活性を有するヘテロ芳香族化合物
TWI659022B (zh) 作為d-胺基酸氧化酶(daao)抑制劑之新穎經取代苯并咪唑衍生物
EP2903969A1 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
US6825192B1 (en) Heterodiazinone derivatives
WO2011008475A1 (en) Optionally substituted 2-(arylmethyl, aryloxy or arylthio) -n- pyridin-2 -yl-aryl acetamide or 2, 2-bis (aryl) -n-pyridin-2-yl acetamide compounds as medicaments for the treatment of eye diseases
EP1142875A1 (en) Cinnamamide derivatives and drug compositions containing the same
CA2083956A1 (en) Amide linked pyridyl-benzoic acid derivatives for treating leukotriene-related diseases
JP6314978B2 (ja) ベンゾチオフェン化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100901

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130610